{"component": "definition", "props": {"groups": [{"samples": [{"hash": "jpnZcbP2zYu", "uri": "/contracts/jpnZcbP2zYu#sales-threshold", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 31.8446273804, "published": true}, {"hash": "ggnshgntmlA", "uri": "/contracts/ggnshgntmlA#sales-threshold", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7494869232, "published": true}, {"hash": "lgwM84kDb46", "uri": "/contracts/lgwM84kDb46#sales-threshold", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7385349274, "published": true}], "snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}], "snippet": "is defined in Section 5.4.2.", "size": 10, "hash": "3b8afc52e42d2fbb6a5434b29d5c9982", "id": 1}, {"samples": [{"hash": "ewtMWO7Ric4", "uri": "/contracts/ewtMWO7Ric4#sales-threshold", "label": "Research Collaboration and License Agreement (Macrogenics Inc)", "score": 24.7563304901, "published": true}, {"hash": "icAucsvv8IG", "uri": "/contracts/icAucsvv8IG#sales-threshold", "label": "Research Collaboration and License Agreement (Macrogenics Inc)", "score": 24.6741962433, "published": true}, {"hash": "5vOFGVJyLAi", "uri": "/contracts/5vOFGVJyLAi#sales-threshold", "label": "Research Collaboration and License Agreement (Macrogenics Inc)", "score": 24.5838470459, "published": true}], "snippet_links": [{"key": "section-533", "type": "clause", "offset": [14, 27]}], "snippet": "is defined in Section 5.3.3.", "size": 5, "hash": "a2ea80d59044a704571f8316838402c2", "id": 2}, {"samples": [{"hash": "cVMxbLJ1nrY", "uri": "/contracts/cVMxbLJ1nrY#sales-threshold", "label": "Research Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "eSvxqoPs2om", "uri": "/contracts/eSvxqoPs2om#sales-threshold", "label": "Research Collaboration and License Agreement (Protagonist Therapeutics, Inc)", "score": 27.6036968231, "published": true}, {"hash": "hGXcAyuCgty", "uri": "/contracts/hGXcAyuCgty#sales-threshold", "label": "Research Collaboration and License Agreement (Protagonist Therapeutics, Inc)", "score": 27.472278595, "published": true}], "snippet_links": [{"key": "set-out", "type": "definition", "offset": [23, 30]}, {"key": "section-731", "type": "clause", "offset": [34, 47]}], "snippet": "shall have the meaning set out in Section 7.3.1.", "size": 5, "hash": "d188b0c98378d369eefbc121dca8924e", "id": 3}, {"samples": [{"hash": "dLVMzhcorwJ", "uri": "/contracts/dLVMzhcorwJ#sales-threshold", "label": "Distribution, License and Supply Agreement (Focal Inc)", "score": 18.0, "published": true}, {"hash": "6lKvjMOhVTo", "uri": "/contracts/6lKvjMOhVTo#sales-threshold", "label": "Distribution, License and Supply Agreement (Focal Inc)", "score": 18.0, "published": true}, {"hash": "5Ad0lZCAUGb", "uri": "/contracts/5Ad0lZCAUGb#sales-threshold", "label": "Distribution, License and Supply Agreement (Focal Inc)", "score": 18.0, "published": true}], "snippet_links": [], "snippet": "shall have the meaning set forth in Section 3(d)(ii).", "size": 3, "hash": "64e3e4435720202c12f2fdc1f9bc1ca1", "id": 4}, {"samples": [{"hash": "ib3o6qlxVJZ", "uri": "/contracts/ib3o6qlxVJZ#sales-threshold", "label": "License Agreement (Allogene Therapeutics, Inc.)", "score": 30.3442840576, "published": true}, {"hash": "hWAQrrYmJk", "uri": "/contracts/hWAQrrYmJk#sales-threshold", "label": "License Agreement (Cellectis S.A.)", "score": 30.3114299774, "published": true}, {"hash": "gjqpYGfA6Qf", "uri": "/contracts/gjqpYGfA6Qf#sales-threshold", "label": "License Agreement (Cellectis S.A.)", "score": 30.1909656525, "published": true}], "snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}], "snippet": "is defined in Section 5.1.2.", "size": 3, "hash": "25f8bfb1e98d3a7be60afda2d379b6ec", "id": 5}, {"samples": [{"hash": "dLVMzhcorwJ", "uri": "/contracts/dLVMzhcorwJ#sales-threshold", "label": "Distribution, License and Supply Agreement (Focal Inc)", "score": 18.0, "published": true}, {"hash": "5Ad0lZCAUGb", "uri": "/contracts/5Ad0lZCAUGb#sales-threshold", "label": "Distribution, License and Supply Agreement (Focal Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "calendar-year", "type": "definition", "offset": [27, 40]}, {"key": "trigger-date", "type": "clause", "offset": [73, 85]}, {"key": "aggregate-net-sales", "type": "definition", "offset": [94, 113]}, {"key": "the-net", "type": "clause", "offset": [183, 190]}, {"key": "exercise-of-the-conversion-right", "type": "clause", "offset": [241, 273]}, {"key": "in-writing", "type": "clause", "offset": [297, 307]}, {"key": "notice-to", "type": "definition", "offset": [349, 358]}, {"key": "upon-exercise", "type": "clause", "offset": [368, 381]}, {"key": "with-respect-to", "type": "clause", "offset": [411, 426]}, {"key": "pursuant-to-section-7", "type": "clause", "offset": [467, 488]}, {"key": "to-pay", "type": "clause", "offset": [528, 534]}, {"key": "the-sale", "type": "clause", "offset": [569, 577]}, {"key": "in-the-territory", "type": "clause", "offset": [578, 594]}, {"key": "the-purchase-price", "type": "clause", "offset": [730, 748]}, {"key": "for-products", "type": "clause", "offset": [817, 829]}, {"key": "equal-to", "type": "definition", "offset": [877, 885]}, {"key": "the-fact", "type": "clause", "offset": [1066, 1074]}], "snippet": "means the decrease, in any calendar year which commences on or after the Trigger Date, in the aggregate Net Sales of all three products by an amount greater than [*] when compared to the Net Sales for the immediately previous calendar year. Exercise of the Conversion Right by Focal shall be made in writing upon no less than thirty (30) days prior notice to Ethicon. Upon exercise of the Conversion Right, (A) with respect to Products that are not supplied by Focal pursuant to Section 7, any royalty that Ethicon is obligated to pay Focal pursuant to Section 6(d) on the sale in the Territory of Products other than [*]) shall be reduced by [*] and (B) with respect to Products that are supplied by Focal pursuant to Section 7, the Purchase Price that Ethicon is obligated to pay Focal pursuant to Section 7(c)(ii) for Products (other than [*]) shall be reduced by an amount equal to [*], if any, that Ethicon would be obligated to pay Focal per unit of such Product pursuant to Section 6(d) (exclusive of any reduction pursuant to this Section 3(d)(ii)), but for the fact that Focal is supplying such Product to Ethicon pursuant to Section 7.", "size": 3, "hash": "0155e89144029411baf367345690fae7", "id": 6}, {"samples": [{"hash": "hHedoKYE4V5", "uri": "/contracts/hHedoKYE4V5#sales-threshold", "label": "Distribution Agreement (Aastrom Biosciences Inc)", "score": 18.0, "published": true}, {"hash": "EMezWcT5qs", "uri": "/contracts/EMezWcT5qs#sales-threshold", "label": "Distribution Agreement (Aastrom Biosciences Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "fiscal-year-1999", "type": "definition", "offset": [107, 123]}, {"key": "fiscal-year-2000", "type": "definition", "offset": [152, 168]}], "snippet": "means (x) $60 million in any Fiscal Year up to and --------------- including 1998, (y) $125 million in the Fiscal Year 1999 and (z) $200 million in the Fiscal Year 2000 and thereafter.", "size": 2, "hash": "a47119a5b7b9efc0c5a6b9e19bb1ddf4", "id": 7}, {"samples": [{"hash": "4P3VRP5xn0n", "uri": "https://www.legis.iowa.gov/docs/aco/bulletin/07-03-2019.pdf", "label": "www.legis.iowa.gov", "score": 7.743326664, "published": false}, {"hash": "6vFjSBQfLa", "uri": "https://www.legis.iowa.gov/docs/iac/chapter/10-21-2020.701.215.pdf", "label": "www.legis.iowa.gov", "score": 6.8254618645, "published": false}], "snippet_links": [{"key": "collection-and-remittance", "type": "clause", "offset": [38, 63]}, {"key": "iowa-sales-tax", "type": "clause", "offset": [80, 94]}, {"key": "local-option-tax", "type": "definition", "offset": [99, 115]}, {"key": "code-section", "type": "definition", "offset": [137, 149]}, {"key": "gross-revenue", "type": "definition", "offset": [182, 195]}, {"key": "the-current", "type": "clause", "offset": [232, 243]}, {"key": "prior-calendar-year", "type": "definition", "offset": [259, 278]}], "snippet": "means the revenue level that triggers collection and remittance obligations for Iowa sales tax and local option tax as described in Iowa Code section 423.14A(3): $100,000 or more in gross revenue from Iowa sales into Iowa in either the current or immediately prior calendar year.", "size": 2, "hash": "d2d674fcaa844ef8da88f21f306d580c", "id": 8}, {"samples": [{"hash": "gAT5PGL0i3J", "uri": "/contracts/gAT5PGL0i3J#sales-threshold", "label": "Lease Agreement (Build a Bear Workshop Inc)", "score": 18.0, "published": true}, {"hash": "ea96tEbVGSy", "uri": "/contracts/ea96tEbVGSy#sales-threshold", "label": "Lease Agreement (Build a Bear Workshop Inc)", "score": 18.0, "published": true}], "snippet_links": [], "snippet": "shall have the meaning set forth in Section 1.5 hereof.", "size": 2, "hash": "50fb99b7c7997c8f4131552e2d3c2635", "id": 9}, {"samples": [{"hash": "egmKuxbEQHm", "uri": "/contracts/egmKuxbEQHm#sales-threshold", "label": "Purchase and Sale Agreement (Milestone Pharmaceuticals Inc.)", "score": 37.2135523614, "published": true}, {"hash": "giEXzSmKFlw", "uri": "/contracts/giEXzSmKFlw#sales-threshold", "label": "Purchase and Sale Agreement (Milestone Pharmaceuticals Inc.)", "score": 34.2429847717, "published": true}], "snippet_links": [{"key": "the-definition-of", "type": "definition", "offset": [14, 31]}, {"key": "net-sales", "type": "definition", "offset": [33, 42]}], "snippet": "is defined in the definition of \u201cNet Sales\u201d.", "size": 2, "hash": "a3a7eaea1bf7ed3d1b3effd5151b844f", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYc2FsZXMtdGhyZXNob2xkIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Sales Threshold", "snippet": "is defined in Section 5.4.2.", "size": 47, "id": "sales-threshold", "examples": ["Each Sales Milestone Payment is payable a maximum of one time only, regardless of the number of times a Licensed Product achieves a particular <strong>Sales Threshold</strong> or the number of Licensed Products that achieve a particular <strong>Sales Threshold</strong>.", "For the avoidance of doubt, the date that any sale shall be deemed to have been effected for purposes of determining whether the Monthly <strong>Sales Threshold</strong> has been achieved in any calendar month and the corresponding, applicable discount to be applied pursuant to the immediately preceding sentence (i.e. 2% or 3%) shall be conclusively determined by the trade date set forth on the relevant confirmation sales ticket, and such determination shall be final and binding upon the parties.", "Each Sales Milestone Payment is payable a maximum of one time only, regardless of the number of Licensed Products that achieve a particular <strong>Sales Threshold</strong>.", "After receipt of such Written Analysis, Oji shall have the option to (i) work with VCP to bolster sales and address any issues raised by VCP in the Written Analysis, (ii) terminate this Agreement, but only if (a) Oji reasonably and in good faith expects that VCP will be unable to meet the <strong>Sales Threshold</strong> in a second consecutive Contract Year and provides VCP with a written analysis supporting such conclusion or (b) VCP has missed the <strong>Sales Threshold</strong> in two consecutive Contract Years.", "Pfizer shall pay to CytomX the following one-time payments (each, a \u201cSales Milestone Payment\u201d) when aggregate Annual Net Sales of a Licensed Product in the Territory in a Pfizer Year first reach the respective threshold (a \u201c<strong>Sales Threshold</strong>\u201d) indicated below (each, a \u201cSales Milestone\u201d); provided that such <strong>Sales Threshold</strong> with respect to a Licensed Product must be reached within the first seven (7) full Pfizer Years following the First Commercial Sale of such Licensed Product in the United States.", "This Milestone Payment shall only be due once, if at all, and shall be due and payable sixty (60) days following the end of the applicable Calendar Year in which the First Net <strong>Sales Threshold</strong> is achieved.", "If the unit volume of Licensed Thermal Paper Products sold or distributed by VCP in the Exclusive Territory during any Contract Year is below the <strong>Sales Threshold</strong>, then VCP shall provide Oji with a written analysis of the reasons for such sales performance (the \u201cWritten Analysis\u201d) within 30 days of the end of such Contract Year.", "This Milestone Payment shall only be due once, if at all, and shall be due and payable sixty (60) days following the end of the applicable Calendar Year in which the Second Net <strong>Sales Threshold</strong> is achieved.", "This Milestone Payment shall only be due once, if at all, and shall be due and payable sixty (60) days following the end of the applicable Calendar Year in which the Fifth Net <strong>Sales Threshold</strong> is achieved.", "Each of the sales based event payments shall be paid no more than once during the Agreement Term, at first occurrence of the event for the Product in the Territory first reaching the respective Net <strong>Sales Threshold</strong>, irrespective of whether or not the previous sales based event payment was triggered by the same or by a different Product, and shall be non-refundable, and shall be paid within [***] after the end of the Calendar Year in which the event first occurs."], "related": [["minimum-threshold", "Minimum Threshold", "Minimum Threshold"], ["bid-threshold", "Bid threshold", "Bid threshold"], ["minimum-takedown-threshold", "Minimum Takedown Threshold", "Minimum Takedown Threshold"], ["vwap-minimum-price-threshold", "VWAP Minimum Price Threshold", "VWAP Minimum Price Threshold"], ["ownership-threshold", "Ownership Threshold", "Ownership Threshold"]], "related_snippets": [], "updated": "2026-03-22T04:42:52+00:00"}, "json": true, "cursor": ""}}